Modalities beyond small molecules

From PROTAC^®s to peptides

Innovative therapeutic approaches are expanding the horizons of drug discovery, incorporating small molecules into groundbreaking modalities such as PROTAC^®s, ADCs and peptide-based structures. Our medicinal chemists bring extensive expertise to these emerging fields, offering tailored chemical solutions to advance your drug development process.

Design and synthesis of degraders, ADCs and peptide libraries

Nuvisan offers a comprehensive suite of chemistry services across various advanced therapeutic modalities:

Proteolysis targeting chimeras (PROTAC^®s)

Optimisation of exit vectors, linker length and composition for oral bioavailability.
Digital Life Sciences support, including:
- Binder design for POIs/E3 ligases
- Structure-based and de novo linker optimisation
- Ternary complex prediction
Proven track record in delivering preclinical PROTAC^® compounds efficiently.

Antibody–drug conjugates (ADCs)

Advanced linker optimisation to reduce systemic exposure and limit toxicity.

Peptide-based drug development

Parallel peptide synthesis in 48/96-well reactors for sequences up to 20 amino acids
Design and incorporation of non-natural amino acids
Specialised expertise in:
- Peptide stapling and cyclic peptide design.
- 18F-labelling for advanced applications.
- SAR generation and PK optimisation for peptide-based small molecules.

These capabilities allow Nuvisan to deliver precise and innovative solutions, driving progress in your drug discovery programs.